Neurology Associates of Ormond Beach

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis6 trials
• Alzheimer disease4 trials

Phase

• Phase 310 trials

Status

• Active, not recruiting5 trials
• Recruiting2 trials
• Completed1 trial
• Suspended1 trial
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals4 trials
• Actelion1 trial
• Eisai Inc.1 trial
• Green Valley (Shanghai) Pharmaceuticals Co., Ltd.1 trial
• Immunic AG1 trial
• and 2 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Heather Schutz

• Active, not recruiting

  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

  NCT06869785· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

  Contact: David McDonald, Site 1204

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05134441· Phase 3· Immunic AG· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting
• Multiple sclerosis1 recruiting

Closed trials

• Completed

  Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

  NCT03232073· Phase 3· Actelion· Source

• Terminated

  Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source